What it sells
AI platform accelerating therapies for rare & inflammatory diseases.
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partners / acquirers and regulators; no product purchase (inferred).
Workflow: what inputs become what output?
AI-assisted discovery of first-in-class p38a:MK2 dual signal modulators, progressed to a Phase 2 ARDS study (GEn-1124 IV).
Economics: what it saves and how it charges
Clinical-stage biotech; value comes from pipeline assets (licensing/partnering/milestones). FDA granted Orphan Drug and Rare Pediatric Disease designations for DMD candidate.
Distribution: how it reaches customers
Partnership and licensing outreach via partners and contact pages.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2019 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.